# IntelliGenome and NL Diagnóstica sign exclusive Brazil distribution deal for CRISPR-TB blood test

> IntelliGenome grants NL Diagnóstica exclusive Brazil distribution rights for its CRISPR-Dx tuberculosis platform, targeting a country.

- Published: 2026-11-02T14:20:48+00:00
- Section: Partnerships
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-02/intelligenome-nl-diagnostica-brazil-tb-deal
- Source: [PR Newswire](https://www.prnewswire.com/news-releases/intelligenome-and-nl-diagnostica-partner-to-advance-tuberculosis-detection-in-brazil-302926409.html)

## Key takeaways

- IntelliGenome signed an exclusive distribution agreement with NL Diagnóstica to advance its CRISPR-Dx platform in Brazil.
- Brazil records approximately 84,000 new tuberculosis cases and 6,000 deaths annually, according to the Ministry of Health.
- The companies will exhibit CRISPR-TB and CRISPR-NTM at the UNION World Conference on Lung Health in Rio de Janeiro on November 17-20, 2026.

IntelliGenome, Inc. has signed an exclusive distribution agreement with NL Diagnóstica to advance its CRISPR-Dx diagnostic platform in Brazil, the companies announced on November 2, 2026. [PR Newswire](https://www.prnewswire.com/news-releases/intelligenome-and-nl-diagnostica-partner-to-advance-tuberculosis-detection-in-brazil-302926409.html) published the announcement. Brazil records approximately 84,000 new tuberculosis cases and 6,000 deaths annually, according to the Ministry of Health.

## How the IntelliGenome-NL Diagnóstica Agreement Works

[IntelliGenome](https://akta.pro/company-profiles/00hfycc/intelligenome) develops CRISPR-based molecular diagnostic technologies, and [NL Diagnóstica](https://akta.pro/company-profiles/0022mxd/nl-diagnostica) is a Brazilian in vitro diagnostics company headquartered in São Paulo with more than 35 years of experience. The exclusive agreement covers the CRISPR-Dx platform in Brazil. The companies are working with Brazilian academic institutions, clinical laboratories and healthcare organizations to evaluate the CRISPR-TB laboratory-based blood test, which detects Mycobacterium tuberculosis complex cell-free DNA. These collaborations include clinical research initiatives involving pediatric tuberculosis, while IntelliGenome continues to advance its point-of-care technology for decentralized healthcare settings.

"Brazil's commitment to tuberculosis elimination creates an important opportunity for diagnostic innovation," said Kurt Wehrle, Senior Vice President, Global Commercialization, IntelliGenome. "Our partnership with NL Diagnóstica combines complementary expertise and strong scientific relationships to advance blood-based CRISPR technology and address critical unmet needs in tuberculosis detection."

Fabio Moruzzi, Chief Commercial Officer of NL Diagnóstica, said many tuberculosis patients, including children and people living with HIV, cannot produce sputum, the sample used in most routine molecular tests. "With blood, sample collection is no longer the obstacle," Moruzzi said. He added that interest from leading Brazilian institutions highlights the potential of CRISPR-TB to advance earlier tuberculosis detection across the country.

## IntelliGenome's Latin America Distribution Record

According to akta.pro [company records](https://akta.pro/company-data), IntelliGenome appointed CTR Scientific as its exclusive distribution partner for the CRISPR-TB Blood Test in Mexico in June 2026. The same records show that Colombia's INVIMA granted sanitary registration No. 2026RD-0009793 for the CRISPR-TB Blood Test Kit in June 2026, enabling a commercial launch, and that Velez Lab S.A.S. was appointed exclusive long-term distribution partner for Colombia that month. The records also list a March 2026 R&D subaward agreement with Cornell University to develop a rapid, low-cost, portable TB diagnostic as part of an NIH-funded program.

## Earlier IntelliGenome Partnerships

In July 2026, IntelliGenome appointed Yu Shing Bio-Tech Co., Ltd. as its exclusive distributor in Taiwan to commercialize its CE-IVDD CRISPR-TB blood test, Newswise reported. That same month, Newswise reported an R&D subaward agreement with Cornell University to develop a rapid, low-cost, portable tuberculosis diagnostic as part of an NIH-funded program. In June 2026, PR Newswire reported that Colombia's INVIMA granted sanitary registration for the CRISPR-TB Blood Test Kit under registration No. 2026RD-0009793, authorizing importation and sale of the assay in Colombia.

## UNION World Conference Exhibit in Rio

IntelliGenome will exhibit its CRISPR-TB and CRISPR-NTM molecular diagnostic technologies at the UNION World Conference on Lung Health, held November 17-20, 2026, in Rio de Janeiro, where the companies will showcase their partnership.

## Companies in this story

- [IntelliGenome company profile](https://akta.pro/company-profiles/00hfycc/intelligenome) · website: https://intelligenome-us.com
- [NL Diagnóstica company profile](https://akta.pro/company-profiles/0022mxd/nl-diagnostica) · website: https://www.nldiagnostica.com.br

---
News for Agent · https://newsforagent.com/llms.txt